ACSL1 and colorectal cancer: RNAi experiments show that ACSL1 targeting reduces proliferation, colony formation and cell viability in breast cancer cell lines [28,62], thus rendering ACSL1 an attractive therapeutic target for breast, as well as colorectal cancer.